These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Fluorine-18-labelled Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography or Magnetic Resonance Imaging to Diagnose and Localise Prostate Cancer. A Prospective Single-arm Paired Comparison (PEDAL). Wong LM, Sutherland T, Perry E, Tran V, Spelman T, Corcoran N, Lawrentschuk N, Woo H, Lenaghan D, Buchan N, Bax K, Symons J, Saeed Goolam A, Chalasani V, Hegarty J, Thomas L, Christov A, Ng M, Khanani H, Lee SF, Taubman K, Tarlinton L. Eur Urol Oncol; 2024 Oct; 7(5):1015-1023. PubMed ID: 38281891 [Abstract] [Full Text] [Related]
4. More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT. Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE. Hell J Nucl Med; 2019 Oct; 22(1):6-9. PubMed ID: 30843003 [Abstract] [Full Text] [Related]
5. Combined Utility of 68Ga-Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography and Multiparametric Magnetic Resonance Imaging in Predicting Prostate Biopsy Pathology. Kalapara AA, Ballok ZE, Ramdave S, O'Sullivan R, Ryan A, Konety B, Grummet JP, Frydenberg M. Eur Urol Oncol; 2022 Jun; 5(3):314-320. PubMed ID: 33741337 [Abstract] [Full Text] [Related]
8. Diagnostic accuracy of 68 Ga-prostate-specific membrane antigen (PSMA) positron-emission tomography (PET) and multiparametric (mp)MRI to detect intermediate-grade intra-prostatic prostate cancer using whole-mount pathology: impact of the addition of 68 Ga-PSMA PET to mpMRI. Scheltema MJ, Chang JI, Stricker PD, van Leeuwen PJ, Nguyen QA, Ho B, Delprado W, Lee J, Thompson JE, Cusick T, Spriensma AS, Siriwardana AR, Yuen C, Kooner R, Hruby G, O'Neill G, Emmett L. BJU Int; 2019 Nov; 124 Suppl 1():42-49. PubMed ID: 31287613 [Abstract] [Full Text] [Related]
9. Detection Rate of 68Ga-PSMA PET/CT vs. mpMRI Targeted Biopsy for Clinically Significant Prostate Cancer. Pepe P, Pepe L, Cosentino S, Ippolito M, Pennisi M, Fraggetta F. Anticancer Res; 2022 Jun; 42(6):3011-3015. PubMed ID: 35641295 [Abstract] [Full Text] [Related]
10. Simultaneous 68Ga-PSMA HBED-CC PET/MRI Improves the Localization of Primary Prostate Cancer. Eiber M, Weirich G, Holzapfel K, Souvatzoglou M, Haller B, Rauscher I, Beer AJ, Wester HJ, Gschwend J, Schwaiger M, Maurer T. Eur Urol; 2016 Nov; 70(5):829-836. PubMed ID: 26795686 [Abstract] [Full Text] [Related]
11. Findings in 1,123 Men with Preoperative 68Ga-Prostate-Specific Membrane Antigen Positron Emission Tomography/Computerized Tomography and Multiparametric Magnetic Resonance Imaging Compared to Totally Embedded Radical Prostatectomy Histopathology: Implications for the Diagnosis and Management of Prostate Cancer. Raveenthiran S, Yaxley WJ, Franklin T, Coughlin G, Roberts M, Gianduzzo T, Kua B, Samaratunga H, Delahunt B, Egevad L, Wong D, McEwan L, Brown N, Parkinson R, Esler R, Yaxley JW. J Urol; 2022 Mar; 207(3):573-580. PubMed ID: 34694140 [Abstract] [Full Text] [Related]
12. 68Ga-PSMA Positron Emission Tomography/Computerized Tomography for Primary Diagnosis of Prostate Cancer in Men with Contraindications to or Negative Multiparametric Magnetic Resonance Imaging: A Prospective Observational Study. Lopci E, Saita A, Lazzeri M, Lughezzani G, Colombo P, Buffi NM, Hurle R, Marzo K, Peschechera R, Benetti A, Zandegiacomo S, Pasini L, Lista G, Cardone P, Castello A, Maffei D, Balzarini L, Chiti A, Guazzoni G, Casale P. J Urol; 2018 Jul; 200(1):95-103. PubMed ID: 29409824 [Abstract] [Full Text] [Related]
14. Protocol for the PRIMARY clinical trial, a prospective, multicentre, cross-sectional study of the additive diagnostic value of gallium-68 prostate-specific membrane antigen positron-emission tomography/computed tomography to multiparametric magnetic resonance imaging in the diagnostic setting for men being investigated for prostate cancer. Amin A, Blazevski A, Thompson J, Scheltema MJ, Hofman MS, Murphy D, Lawrentschuk N, Sathianathen N, Kapoor J, Woo HH, Chalasani V, Rasiah K, van Leeuwen PJ, Tang R, Cusick T, Stricker P, Emmett L. BJU Int; 2020 Apr; 125(4):515-524. PubMed ID: 31957122 [Abstract] [Full Text] [Related]
15. Targeted prostate biopsy: 68Ga-PSMA PET/CT vs. mpMRI in the diagnosis of prostate cancer. Pepe P, Pepe L, Tamburo M, Marletta G, Pennisi M, Fraggetta F. Arch Ital Urol Androl; 2022 Sep 26; 94(3):274-277. PubMed ID: 36165469 [Abstract] [Full Text] [Related]
18. The PRIMARY Score: Using Intraprostatic 68Ga-PSMA PET/CT Patterns to Optimize Prostate Cancer Diagnosis. Emmett L, Papa N, Buteau J, Ho B, Liu V, Roberts M, Thompson J, Moon D, Sheehan-Dare G, Alghazo O, Agrawal S, Murphy D, Stricker P, Hope TA, Hofman MS. J Nucl Med; 2022 Nov 26; 63(11):1644-1650. PubMed ID: 35301240 [Abstract] [Full Text] [Related]
19. The Additive Diagnostic Value of Prostate-specific Membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre Study. Emmett L, Buteau J, Papa N, Moon D, Thompson J, Roberts MJ, Rasiah K, Pattison DA, Yaxley J, Thomas P, Hutton AC, Agrawal S, Amin A, Blazevski A, Chalasani V, Ho B, Nguyen A, Liu V, Lee J, Sheehan-Dare G, Kooner R, Coughlin G, Chan L, Cusick T, Namdarian B, Kapoor J, Alghazo O, Woo HH, Lawrentschuk N, Murphy D, Hofman MS, Stricker P. Eur Urol; 2021 Dec 26; 80(6):682-689. PubMed ID: 34465492 [Abstract] [Full Text] [Related]
20. Intraindividual comparison between 68Ga-PSMA-PET/CT and mpMRI for intraprostatic tumor delineation in patients with primary prostate cancer: a retrospective analysis in 101 patients. Spohn S, Jaegle C, Fassbender TF, Sprave T, Gkika E, Nicolay NH, Bock M, Ruf J, Benndorf M, Gratzke C, Grosu AL, Zamboglou C. Eur J Nucl Med Mol Imaging; 2020 Nov 26; 47(12):2796-2803. PubMed ID: 32342192 [Abstract] [Full Text] [Related] Page: [Next] [New Search]